{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "ANRO",
  "name": "Alto Neuroscience Inc.",
  "url": "https://orbyd.app/dossiers/ANRO/",
  "json_url": "https://orbyd.app/dossiers/ANRO.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Precision-psychiatry re-rate (~10x off $2.85) re-armed on 2026-07-13 — a successful FDA meeting cleared an additional ALTO-207 monotherapy Phase 3 in TRD, funded same-day by a $100M raise at $26.48. Narrative refreshed, but every data readout is 2027 and shares sit just under the $28.85 high on ~11% fresh dilution. Anticipatory, not catalyst-driven.",
  "invalidation_trigger": "A weekly close below $20 breaks the launch base and ends the precision-psychiatry re-rate leg; secondary confirmation is the theme rolling to SATURATED or ALTO-207 Phase 3 site-initiation momentum stalling into the 2027 readouts.",
  "catalyst_date": "2026-08-13",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics",
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "2026-07-13: $100M registered direct offering priced (3,776,436 sh @ $26.48, ~$93.9M net, led by BofA Securities), closed ~07-14. Pro forma cash ~$338M; runway extended into Phase 3 / potential NDA.",
    "2026-07-13: successful FDA meeting -> plans for an additional ALTO-207 Phase 3 as monotherapy in TRD (on top of adjunctive). Regulatory alignment on program design; management raising at highs is a valuation tell.",
    "Stretched near 52-week high ($28.44) after ~10x off $2.50 low with no near-term catalyst — chase risk. Best R/R is a pullback to base or approach into a 2027 catalyst window, not strength near ATH.",
    "Sell-side: 9 analysts, Strong Buy, avg PT ~$35 (range $21 Wedbush to $50 HC Wainwright); Baird $38 post-ALTO-101.",
    "Next print ~2026-08-13 (est.), Q2 2026 — low-information: preliminary cash (~$244.2M at 6/30/26) already pre-released 2026-07-13 with the offering; pre-revenue, no efficacy data due.",
    "All value-inflection readouts are 2027: ALTO-300 ~1H27, ALTO-100 ~mid-27, ALTO-207 Phase 3 data 2H27+. No binary catalyst inside 30 days.",
    "ALTO-101 (schizophrenia/CIAS) failed Phase 2 primary April 2026 (theta-ITC p=0.052 near-miss); independent development dropped, partnering only. Platform does not always translate.",
    "Q1 2026 net loss $26.2M, R&D $20.3M (from $10.0M YoY), EPS -$0.80 vs -$0.54 est. ~$20M/qtr burn scaling with trials; monotherapy Phase 3 lifts run-rate.",
    "Sell-side: 9 analysts, consensus Strong Buy, avg PT ~$35 (range $21 Wedbush to $50 HC Wainwright; Baird $38).",
    "52-week range $2.85-$28.85; ~10x off the low; ~39M shares post-raise, market cap ~$1.06B (~$27.07 on 2026-07-21). Best R/R is a pullback into the low-$20s base or an approach into a 2027 catalyst, not strength near ATH."
  ],
  "body_markdown": "## Current Thesis\nAlto is a precision-psychiatry re-rate that already ran roughly 10x off a $2.85 low into the high-$20s, and on July 13, 2026 it re-armed the story on two fronts at once: a successful FDA meeting cleared the path for an **additional ALTO-207 Phase 3 as monotherapy** in treatment-resistant depression, and the company funded that expansion the same day with a **$100M registered direct offering priced at $26.48**. The narrative got a fresh regulatory + capital injection, yet the tape barely moved — shares sit around $27.07 (July 21), just under the $28.85 52-week high. The problem for a buyer at these levels is unchanged and now compounded by ~11% fresh dilution: every value-inflection readout — ALTO-300, ALTO-100, ALTO-207 Phase 3 — lands in 2027. Price near the high is paying for data that is a year-plus out. This is a maturing momentum name digesting supply, re-armed but not breaking out.\n\n## Bull Case\n- **FDA alignment de-risked the program (2026-07-13).** Alto announced plans to accelerate and expand ALTO-207 development in TRD following a successful FDA meeting, including a planned additional Phase 3 trial as monotherapy. Regulatory agreement on trial design is a meaningful step for a clinical-stage name — it converts a single adjunctive Phase 3 into a two-pronged TRD program.\n- **Balance sheet extended into the binaries.** The July 13 registered direct offering (3,776,436 shares at $26.48, led by BofA Securities) raised ~$93.9M net and closed ~2026-07-14. Preliminary cash was ~$244.2M at 6/30/2026; pro forma for the raise, cash sits near ~$338M — runway comfortably through the 2027 reads and into Phase 3 / a potential NDA. Near-term dilution risk is now largely spent.\n- **Differentiated lead asset.** Management positions ALTO-207 as one of the largest independently validated efficacy signals reported in TRD; the expanded design tests both adjunctive and monotherapy settings, widening the addressable label if the data holds.\n- **Platform validation in print.** June 15, 2026 Nature Medicine publication of the ALTO-203 pramipexole trial in MDD with clinically significant anhedonia identified a patient-selection biomarker tied to EEG theta/beta ratio — support for the precision-selection thesis rather than a single-drug bet.\n- **Sell-side skews bullish.** 9 analysts, consensus Strong Buy, average PT ~$35 (range $21 Wedbush to $50 HC Wainwright); Baird carried $38 even after the ALTO-101 miss, framing the depression pipeline as the valuation driver.\n\n## Bear Case\n- **The 10x already happened.** From $2.85 to ~$27 with the first binary still in 2027. Buyers near the $28.85 high are financing 2027 outcomes with 2026 dollars and no near-term data to bridge the gap.\n- **Management raised into strength.** Selling 3.776M new shares (~11% of the ~35.1M base) at $26.48 the same day it announced the expansion is a tell about how insiders value the paper. Share count is now ~39M, market cap ~$1.06B. Raising at the high funds the science but caps the near-term upside.\n- **A fresh miss sits in the tape.** ALTO-101 (cognitive impairment in schizophrenia) failed its Phase 2 primary EEG/cognitive endpoints in April 2026 (theta-ITC, p=0.052 — a near-miss, not a hit); Alto dropped independent development and is partnering only. The biomarker platform does not always translate.\n- **No revenue, widening burn.** Q1 2026 net loss $26.2M, R&D $20.3M (up from $10.0M YoY), EPS -$0.80 vs -$0.54 est. Adding a monotherapy Phase 3 raises the run-rate; a ~$20M/quarter burn scales with the pipeline.\n- **Catalyst desert.** Nothing binary between now and the 2027 reads (ALTO-300 ~1H27, ALTO-100 ~mid-27, ALTO-207 Phase 3 data 2H27 and beyond). Between catalysts a clinical-stage biotech at highs tends to bleed premium; Wedbush's $21 target already sits below the quote.\n\n## Setup & Price Structure\nShares traded ~$27.07 on July 21, 2026, roughly 6% under the $28.85 52-week high, after the July 13 offering priced at $26.48. Both the FDA-driven expansion and the raise hit the tape the same day, and price is close to flat since — the narrative re-armed without producing a new breakout leg. The chart reads as a completed recovery consolidating near its high: a base built off $2.85, a multi-quarter re-rate, and now sideways digestion of ~11% fresh supply from the registered direct. That is maturing momentum absorbing a placement, not an accelerating breakout with cluster confirmation behind it. The higher-probability entry is a pullback into the low-$20s launch shelf that holds and turns up, or an approach into a dated 2027 catalyst window — buying strength near the ATH into fresh dilution, with the first data a year out, is a chase. Best to stand aside for fresh entries at these levels.\n\n## Catalyst Calendar (next 30 days)\n\n- **~2026-08-13 (est.): Q2 2026 results / 10-Q.** Low-information print — preliminary cash (~$244.2M at 6/30) was already pre-released July 13 alongside the offering, and the company is pre-revenue with no efficacy data due. Not thesis-driving.\n- **No binary clinical readout inside 30 days.** The near-term narrative feed is qualitative: ALTO-207 Phase 3 (monotherapy) protocol finalization and site-initiation cadence — no fixed date, watch for updates.\n- **2027 (outside window, the real inflections): ALTO-300 ~1H27, ALTO-100 ~mid-27, ALTO-207 Phase 3 data 2H27+.**\n\n## Elapsed catalysts\n\n- **2026-07-14 (done): offering close / float increase.** ~3.78M-share settlement is already working through the tape as near-term supply. *(passed 26d ago)*\n\n## What Would Change Our Mind\n- **A weekly close below $20** breaks the launch base and ends the precision-psychiatry re-rate leg — the structural signal to stand aside. Secondary confirmation: the theme rolling to SATURATED (mainstream/retail coverage peaking, CNS peers rolling over) with no fresh data.\n- **ALTO-207 Phase 3 momentum stalling** — slipping site-initiation or enrollment timelines into the 2027 window — would crack the one narrative currently carrying the name.\n- **Another pipeline miss** in the ALTO-101 mold would reopen the platform-translation doubt and compress the multiple regardless of cash.\n- **Constructive re-engagement, not strength-chasing:** a clean pullback into the low-$20s that holds and turns up, or the approach into a dated 2027 readout, is the setup worth waiting for. Current-price entries near the ATH into fresh dilution carry poor risk/reward.\n\n## Correlation Notes\n- **Long-duration biotech beta.** ANRO moves with XBI/IBB and rate-cut expectations; pre-revenue CNS names are sensitive to real yields, so rising real rates or a risk-off tape compress the multiple independent of pipeline progress.\n- **Idiosyncratic single-asset dominance.** Day-to-day correlation to broad indices is low; the swing factor is ALTO-207 TRD data (2027). Sentiment reads through CNS/precision-psychiatry peers (Axsome, Sage, Relmada history) more than through the S&P.\n- **Placement overhang.** The ~11% float increase from the July 13 registered direct adds near-term supply; watch participant flow and any follow-on signaling as a distribution tell.",
  "first_seen": "2026-07-10",
  "last_analyzed": "2026-07-26T11:42:51+00:00",
  "last_synthesized": "2026-07-26",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}